push tirzepatide Switch to in T2D More Effective Than Upping Dulaglutide Dose Tirzepatide for Medical Weight Loss

Key Highlights Three once-monthly injections achieved placebo-adjusted weight loss of up to 6.3% at Week 12, increasing to 7.5% at Week 16 Weight loss maintained up to 4 months after the final dose, supporting once-quarterly maintenance therapy potential No weekly lead-in dosing required, differentiating ASC30 from many current GLP-1 regimens Safety profile consistent with the GLP-1 class, with mild-to-moderate adverse events and no discontinuations Why It Matters: Convenience advantage: Monthly or quarterly dosing could significantly improve adherence vs weekly GLP-1 injections Small-molecule innovation: ASC30 is a GLP-1 biased small molecule, enabling both oral and injectable formulations Platform validation: Supports Ascletis Ultra-Long-Acting Platform (ULAP) for developing long-duration metabolic therapies Key Takeaway: ASC30 highlights the next frontier in obesity therapeuticsultra-long-acting incretin therapies

Liver function tests, including ALT, AST, GGT, and ALP, provide objective measures of liver health that can be tracked over time

it requires ongoing education and a supportive network to ensure optimal results

Since retatrutide is still in clinical trials, semaglutide remains the more proven and accessible option

Mounjaro, the brand name for tirzepatide, is a drug that is used to treat type 2 diabetes by lowering blood sugar levels

Notably, neonatal ketogenesis possesses unique characteristics: it can be readily activated even in the non-fasting state, providing essential protective effects during the metabolically vulnerable perinatal period